Key result
The M235T variant of the angiotensinogen gene in either donor or recipient was not associated with the presence or severity of post-transplant hypertension (overall incidence 78%).
Why the study?
Does the M235T variant of the angiotensinogen gene increase the risk of post-transplant hypertension in patients undergoing renal transplantation?
Cohort (n=269)
Blinded review
Does the M235T variant of the angiotensinogen gene increase the risk of post-transplant hypertension in patients undergoing renal transplantation?
The M235T variant of the angiotensinogen gene is not associated with the development of post-transplant hypertension or graft survival in kidney transplant recipients.
Does not support M235T genotyping for post-transplant hypertension risk; leaves open contributions from other genetic or environmental factors.
BACKGROUND: The angiotensinogen gene has been linked to the development of essential hypertension, and a M235T variant of this gene, associated with increased plasma levels of angiotensinogen, is more common in hypertensives than in normotensive controls in various populations. The present study was conducted to examine whether the M235T variant of the angiotensinogen gene may be a risk factor for the development of hypertension in patients undergoing renal transplantation. METHODS: DNA for genetic analysis was prospectively collected from 269 consecutive patients undergoing kidney transplantation between 1988 and 1993 and their corresponding donors. Presence of hypertension and graft survival was analysed by blinded review of all case records over a follow-up period up to 30 months. Angiotensinogen genotype was determined by a mutagenically separated allele-specific polymerase-chain-reaction technique. RESULTS: While post-transplant hypertension was present in 78% of all patients, no relationship was found between either donor or recipient genotype and the presence or severity of post-transplant hypertension. Furthermore, there was no relationship between angio-tensinogen genotype and graft survival during the course of the study. CONCLUSIONS: These findings do not support the hypothesis that the M235T variant of the angiotensinogen gene is a risk factor for the development of post-transplant hypertension.
No takes yet. Share an insight, caveat, or question.
Beige et al. (1996) conducted a cohort in Post-transplant hypertension (n=269). M235T variant of the angiotensinogen gene vs. Other genotypes was evaluated on Presence or severity of post-transplant hypertension. The M235T variant of the angiotensinogen gene in either donor or recipient was not associated with the presence or severity of post-transplant hypertension (overall incidence 78%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: